(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/278987 A1

(51) International Patent Classification:
A61K 31/4745 (2006.01) *A61P 25/18* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/US2022/073209

(22) International Filing Date:
28 June 2022 (28.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/216,875	30 June 2021 (30.06.2021)	US
63/242,794	10 September 2021 (10.09.2021)	US
63/276,079	05 November 2021 (05.11.2021)	US
63/362,561	06 April 2022 (06.04.2022)	US

(71) Applicant: **NEUROCRINE BIOSCIENCES, INC.** [US/US]; 12780 El Camino Real, San Diego, California 92130 (US).

(72) Inventor: **ANGELOV, Angel S.**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US).

(74) Agent: **DAVEY, PH.D., Evan A.** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2023/278987 A1

(54) Title: VALBENAZINE FOR USE IN THE ADD-ON TREATMENT OF SCHIZOPHRENIA

(57) Abstract: Provided herein are methods for the add-on treatment of schizophrenia using a vesicular monoamine transporter isoform 2 (VMAT2) inhibitor. In certain embodiments, the VMAT2 inhibitor is valbenazine or a pharmaceutically acceptable salt thereof.